Merrimack Pharmaceuticals
Company type | Public |
---|---|
Traded as | Nasdaq: MACK Russell Microcap Index component |
Industry | Pharmaceuticals |
Founded | 2000 in Cambridge, Massachusetts |
Headquarters | Cambridge, Massachusetts , United States |
Number of employees | 426 (2016) |
Website | merrimack |
Merrimack Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.
Merrimack's first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in the European Union the following year.[1][2]
History
Merrimack was founded by a group of scientists from MIT and Harvard University in 2000.[3]
In 2016, Merrimack had 426 full-time employees, 103 of which had an MD or PhD.[3]
In October 2016, CEO Robert Mulroy resigned and the company announced they would be laying off 20% of its employees.[4] In January 2017, interim CEO Gary Crocker resigned and the board of directors appointed Richard Peters to be president and CEO. Peters previously worked at Sanofi and was a faculty member at Harvard University.[5]
In January 2017, French pharmaceutical company Ipsen announced they would be purchasing Onivyde from Merrimack for approximately $1 billion.[6]
On November 13, 2018, the statistical programming director Songjiang Wang, received "six months in prison and one year supervised released" after a guilty verdict was handed down to Wang from a United States District Judge in July 2018 for securities fraud and conspiracy to commit securities fraud.[7] Also on December 20, 2019, the United States Securities and Exchange Commission charged Wang with Insider trading.[8]
Pipeline
Merrimack has four drugs in clinical development.
- MM-302 – HER2 targeting antibody-drug conjugate
- MM-121 (seribantumab) – anti-HER3 monoclonal antibody
- MM-141 (istiratumab) – IGF-1R and HER3 bispecific monoclonal antibody
- MM-151 – anti-EGFR mixture of monoclonal antibody
References
- ^ "Investors - Merrimack".
- ^ "Onivyde pegylated liposomal EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 19 June 2020.
- ^ a b "Merrimack - Annual Report". Archived from the original on 2017-02-03. Retrieved 2017-02-02.
- ^ Jamerson, Joshua (3 October 2016). "Merrimack Pharmaceuticals Cuts Jobs; CEO Resigns Amid Restructuring Effort". Wall Street Journal.
- ^ "Merrimack - Current Report". Archived from the original on 2017-02-03. Retrieved 2017-02-02.
- ^ "Ipsen to buy some Merrimack assets for about $1 billion". Reuters. 9 January 2017.
- ^ "Former Biopharma Statistical Programmer Sentenced for Insider Trading". United States Department of Justice. November 13, 2018. Retrieved December 20, 2019.
- ^ "Former Biopharmaceutical Executive Charged with Insider Trading". U.S. Securities and Exchange Commission. December 20, 2019. Retrieved December 20, 2019.
- v
- t
- e
- Abbott Laboratories
- AbbVie Inc.
- Acorda Therapeutics
- Advaxis
- Alcon
- Alexion
- Alnylam
- Amgen
- Amneal Pharmaceuticals
- Avax Technologies
- Baxter
- BioCryst
- Biogen
- Bioverativ
- Biovest
- Biovista
- Bristol Myers Squibb
- Century
- Ceragenix
- Combe
- CytoSport
- CytRx
- Danco Laboratories
- Eli Lilly
- Galena Biopharma
- Genentech
- Gilead Sciences
- Ionis
- Institute for OneWorld Health
- Intercept
- Johnson & Johnson
- Kinetic Concepts
- McKesson
- Melinta Therapeutics
- Melior Discovery
- Mentholatum
- Merck & Co.
- Merrimack Pharmaceuticals
- Myriad Genetics
- Moderna
- Northwest Biotherapeutics
- Norwich Pharma
- NovaBay
- Organon
- Ovation
- Pfizer
- Pharmaceutical Product Development
- Prasco Laboratories
- Procter & Gamble
- Proteon Therapeutics
- Purdue Pharma
- Quark
- Regeneron
- RespireRx
- Sarepta Therapeutics
- Sheffield
- Spectrum
- Tec Laboratories
- Titan
- Trevena Inc
- Ultragenyx
- Upsher-Smith
- Ventria Bioscience
- Vertex
- Viatris
- West Pharmaceutical Services
Tax inversion |
|
---|---|
Other |
|